# Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)

> **NCT04541797** · NA · ACTIVE_NOT_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 160 (estimated)

## Conditions studied

- Type 2 Diabetes
- Microvascular Coronary Artery Disease

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo
- **DIAGNOSTIC_TEST:** Stress Cardiac Magnetic Resonance

## Key facts

- **NCT ID:** NCT04541797
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2024-05-08
- **Final completion:** 2025-02-28
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541797, "Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04541797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*